| DIRECT COMPETITOR COMPARISON | |
| ONXX | Pvt1 | OSIP | PFE | Industry | | Market Cap: | 1.75B | N/A | 1.92B | 147.27B | 100.26M | | Employees: | 197 | 11,1741 | 491 | 81,800 | 68 | | Qtrly Rev Growth (yoy): | 36.20% | N/A | 17.80% | -2.90% | 19.70% | | Revenue (ttm): | 232.72M | 13.42B1 | 402.62M | 45.82B | 14.01M | | Gross Margin (ttm): | 34.52% | N/A | 97.76% | 86.61% | 65.67% | | EBITDA (ttm): | -9.08M | N/A | 146.47M | 21.31B | -12.30M | | Oper Margins (ttm): | -4.54% | N/A | 34.98% | 37.42% | -149.46% | | Net Income (ttm): | -8.52M | N/A | 423.35M | 8.09B | N/A | | EPS (ttm): | -0.147 | N/A | 6.486 | 1.204 | -0.33 | | P/E (ttm): | N/A | N/A | 5.10 | 15.16 | 16.37 | | PEG (5 yr expected): | 1.98 | N/A | 1.83 | 5.88 | 1.31 | | P/S (ttm): | 7.64 | N/A | 4.76 | 3.27 | 9.35 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | 12 Years Of Patent Protection For Biologics Based Research And Development Creates Buying Opportunity In Biotech Stocks
Sat 10:34am -
Wall Street Transcript | | • | OSIP | | Less Toxic Monoclonal Antibodies And Increased Patent Protection For Biologics Creates Multiple Positive Investment Scenarios In Biotechnology Sector
Sat 10:23am -
Wall Street Transcript | | • | PFE | | The fall of the world's best-selling drug
Fri, Nov 27 -
at FT.com | | • | PFE | | This Week's 5 Dumbest Stock Moves
Fri, Nov 27 -
at Motley Fool | | • | PFE | | Discover This Secret Weapon for Your Portfolio
Fri, Nov 27 -
at Motley Fool | | • | PFE | | 3 China Profit Plays
Fri, Nov 27 -
at Motley Fool | | • | OSIP | | OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
Thu, Nov 19 -
Business Wire | | • | OSIP | | OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Mon, Nov 16 -
Business Wire | | • | OSIP | | Healthcare Guru Adds Selected Biotech, Pharma Stakes
Wed, Nov 11 -
Indie Research | | • | OSIP | | OSI PHARMACEUTICALS INC Financials
Wed, Nov 11 -
EDGAR Online Financials | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
